Palvella Therapeutics, Inc. Price & Performance (PVLA)

Stifel analysts have initiated coverage on Palvella Therapeutics with a Buy rating and a $45 price target. The company’s lead product, QTORIN™, shows promise for treating rare skin diseases. With ongoing Phase 3 and Phase 2 trials, analysts see significant potential for rapid market value growth.123

Palvella Therapeutics' stock has surged by 12% recently, increasing its market cap by $33 million. Insider buying, including a major purchase by the board chairman, highlights confidence in the company’s growth. The stock now trades near its 52-week high, reflecting optimism around its innovative treatments.456

Palvella Therapeutics continues to garner positive ratings, with analysts setting an average price target of $43.20. The company’s QTORIN™ platform, targeting rare skin diseases, is in advanced clinical trials. With a market cap of $305 million, investors are closely watching its progress toward regulatory milestones.78